Higher dopamine transporter density in Parkinson’s disease patients with depression
✍ Scribed by Andre C. Felicio; Tais S. Moriyama; Clecio Godeiro-Junior; Ming C. Shih; Marcelo Q. Hoexter; Vanderci Borges; Sonia M. A. Silva; Edson Amaro-Junior; Luiz A. F. Andrade; Henrique B. Ferraz; Rodrigo A. Bressan
- Publisher
- Springer
- Year
- 2010
- Tongue
- English
- Weight
- 132 KB
- Volume
- 211
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Parkinson's disease (PD) is a disabling neurodegenerative condition commonly complicated by the existence of comorbid depression. The prevalence rates of depression in this patient group have been reported to be as high as 40%. Currently, depression in PD is undertreated; there have been few control
## Abstract Altered levels of the neurotransmitters dopamine and serotonin are observed in both Parkinson's disease (PD) and depression. Therefore, the neurotransmitter transporter genes, __SLC6A3__ (dopamine) and __SLC6A4__ (serotonin) are candidates for depression in PD. We genotyped 24 tagging S
## Abstract Impaired initiation and slowed execution of movements are two of the principal characteristics of Parkinson's disease (PD). A similar pattern of movement impairments (psychomotor retardation) can be seen frequently in patients with idiopathic depression. In addition, affective disorders
## Abstract The prevalence of depression in Parkinson's disease (PD) varies greatly. In this study, we investigated major depressive disorder (MDD) and depressive symptoms without MDD in patients with PD. The psychopathological characteristics of depressive symptoms were assessed by a psychiatric i